Direct Comparison of TG and WFO LASIK

June 3, 2021 updated by: Chao-Kai Chang, Taipei Nobel Eye Clinic

Contralateral Comparison of Togoguided LASIK and Wavefront-optimized LASIK

To compare the efficacy to different profiles, direct head-to-head studies had been conducted. In one previous review study revealed that TG LASIK provided patient with better uncorrected visual acuity (UCVA) than WFO LASIK and WFG LASIK. In recent previous contralateral eye studies also showed that TG LASIK induced less postoperative higher-order aberration than WFO LASIK. However, these studies included only low-to-moderate myopia patients, for patients with high myopia (spherical equivalent > 6D), the effect of TG LASIK comparing with WFO LASIK had not been reported before.

The aim of our study is to analyze and compare the visual performance of TG LASIK and WFO LASIK in high myopia and low-to-moderate myopia patients, , particularly UCVA, corrected distance visual acuity (CDVA), contrast sensitivity (CS), and wavefront aberration.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Taipei, Taiwan
        • Taipei Nobel Eye Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age between 20 and 50 years old
  • CDVA of both eyes could reach 0.1 logarithm of the minimum angle of resolution (logMAR)
  • stable refractive errors of myopia and astigmatism

Exclusion Criteria:

  • cataract
  • corneal opacities or irregularities
  • dry eye (Schirmer's test I ≤ 5mm)
  • amblyopia
  • coexisting ocular pathologies
  • glaucoma
  • non-dilating pupil
  • history of intraocular surgery, laser therapy, or retinopathy
  • optic nerve or macular diseases
  • estimated postoperative cornea residual stromal thickness less than 250 μm
  • pregnancy or under lactation
  • uncontrolled diabetic mellitus or systemic immune disease
  • refusal or unable to maintain follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Topoguided LASIK
Topoguided ablation profile on dominant eye
Device: Topoguided LASIK
Topoguided ablation profile on dominant eye
Active Comparator: Wavefront optimized LASIK
Wavefront optimized ablation profile on non-dominant eye
Device: Wavefront optimized LASIK
Wavefront optimized ablation profile on non-dominant eye

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual acuity
Time Frame: 3 months after surgery
uncorrected visual acuity and corrected distance visual acuity
3 months after surgery
Corneal wavefront analysis
Time Frame: 3-months postoperative visit
horizontal coma aberration (Z 3,1), spherical aberration (Z 4,0), and trefoil aberration
3-months postoperative visit
Contrast sensitivity
Time Frame: 3-months postoperative visit
4 spatial frequencies: 3, 6, 12, and 18 cycles per degree (cpd).
3-months postoperative visit
Quality of vision questionnaire
Time Frame: 3-months postoperative visit
A 11-item questionnaire, item scores range from 0 to 10 and higher item scores in questionnaire indicated more difficulty in achieving specific visual tasks
3-months postoperative visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Taipei Nobel Eye Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 26, 2019

Primary Completion (Actual)

March 14, 2020

Study Completion (Actual)

June 30, 2020

Study Registration Dates

First Submitted

March 23, 2021

First Submitted That Met QC Criteria

June 3, 2021

First Posted (Actual)

June 9, 2021

Study Record Updates

Last Update Posted (Actual)

June 9, 2021

Last Update Submitted That Met QC Criteria

June 3, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 002 (University of CT Health Center)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Keratomileusis, Laser In Situ

Clinical Trials on Topoguided LASIK

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe